As well, GBA needs to be considered in all aspects of any life cycle approach to drug/product regulation. Implications and requirements for a progressive licensing framework. h. ###>De plus, SCan dispose de lignes directrices actuelles sur «l'Inclusion des femmes dans les essais cliniques » (1997).